To raise awareness within your own local community, why not send a letter to the Editor?
DPAC has made it easy for you to do – we’ve created the letter for you and made it a fillable PDF.
Simply click on the link below, which will take you a secure PDFFiller website.
Follow the instructions and download or print to send to the local news!
As a person with diabetes, I’m writing to express my concern over the dangerous path insurance companies are headed down of limiting access to appropriate devices with establishing preferred provider agreements. The American Diabetes Association’s 2016 Standards of Care call for “Patient-Centeredness,” go on, “recognizing that one size does not fit all.” Those standards of care clearly state, “Treatment decisions should be timely and based on evidence-based guidelines that are tailored to individual patient preferences, prognoses, and comorbidities.” Insurance payers should not preclude physicians from following the best practices defined by most current standards of care.
Most people with diabetes would argue that the availability of a wide spectrum of insulin pumps and continuous glucose monitors (CGM) fosters our care teams’ ability to provide the patient centric care envisioned by the standards of care. Further, it facilitates a more robust market for new technologies and revolutionary advancements. These agreements limiting appropriate access set a dangerous precedent, potentially blocking the next generation of insulin pumps and CGM, which might include smartphone integrations and nano-pump technology which limit advancements across the entire medical continuum, not just within the scope of diabetes.
In the 2016 Standards of Care from the American Diabetes Association, the guidelines state: “Clinical practice guidelines are key to improving population health; however, for optimal outcomes, diabetes care must be individualized for each patient.” When healthcare professionals’ prescribed treatment plans are overridden by healthcare companies through preferred provider agreements, patient outcomes suffer.
I strongly urge health insurance companies to follow the standards of care for diabetes in decision making and reconsider preferred provider agreements because their patients rely on an open and competitive marketplace for the best technology and treatments. Patients’ overall quality of life is improved when they have access to the technology prescribed to them by medical professionals. Without innovation, there is no competition. And without competition, there is no possibility for better outcomes for the patients.
(Don’t forget to add your printed name and address at the bottom of the letter!)